The global urinary drugs market is anticipated to grow at a considerable CAGR of 4.2% during the forecast period (2022-2028). Urinary drugs are the medicine used for the treatment of several urinary diseases including some common diseases such as cystitis, urinary incontinence, overactive bladder, interstitial cystitis, and others. The major factor attributing to the growth of the global urinary drugs market is the rising prevalence of urinary incontinence across the globe. According to the Global Forum on Incontinence (GFI), Urinary Incontinence is a disorder causing loss of bladder control and affects around 400 million people globally, which represents around 4% to 8% of the global population. These diseases are more prevalent in the elderly population.
In addition, several approvals from the US Food and Drug Administration (FDA) are further propelling the growth of the global urinary drugs market. For instance, in December 2020, Strides Pharma Global Pte Ltd. got the FDA approval for Oxybutynin Chloride Tablets USP, 5 mg for the treatment of symptoms from overactive bladder or urinary incontinence. Similarly, in February 2022, Alembic Pharmaceuticals got the tentative approval for Abbreviated New Drug Application (ANDA) from the FDA for Pfizer Inc.’s 4 mg and 8 mg Fesoterodine Fumarate Extended-Release (ER) tablets. These fesoterodine fumarate ER tablets can be used for the treatment of several symptoms of overactive bladder (OAB) including urging urinary incontinence, urgency, and frequency.
Some of the major players in the market include Sanofi SA, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Johnson & Johnson Pvt. Ltd., among others. These market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, new product launches and collaborations, to stay competitive in the market. For instance, in December 2021, Camber Pharmaceuticals launched Tolterodine Tartrate Immediate-Release (IR) tablets for use in the treatment of overactive bladder. Tolterodine tartrate IR tablets are the generic form of “Detrol” and are offered in 1 mg and 2 mg strength with 60 tablet counts in a bottle.
(Get 15% Discount on Buying this Report)
Get Sample Copy of urinary drugs market at:
https://orionmarketreports.com/request-sample/?id=99813&submit=Request+Sample%0D%0A
Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Type of Drug
By Dosage Form
By End-User
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World
Competitive Landscape
Sanofi SA, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Johnson & Johnson Pvt. Ltd., among others.
Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?
A full report of urinary drugs market is available at:
https://orionmarketreports.com/global-urinary-drugs-market/99813/
Global Urinary Drugs Market Report by Segment
By Type of Drug
Oxybutynin
Tolterodine
Darifenacin
Fesoterodine
Others
By Dosage Form
Oral
Injection
By End-User
Hospitals
Clinics
Others
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
